Despite the absence of significant differences in T or N stage, our findings are consistent with the majority of studies and support a strong association between HER2-low status and HR positivity in breast cancer (Peiffer et al., 2023; Won et al., 2022). Here, ERBB2 is linked to breast carcinoma.